Sarepta Therapeutics Inc SRPT

NAS: SRPT | ISIN: US8036071004   30/04/2025
62,40 USD (+2,55%)
(+2,55%)   30/04/2025

12 april 2025 · SRPT Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm · Persbericht

29 mei 2024 · Sarepta Therapeutics Set to Join S&P MidCap 400 · Persbericht

5 november 2023 · ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT · Persbericht

3 november 2023 · SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT · Persbericht

30 augustus 2023 · Quest Diagnostics Granted FDA Breakthrough Designation for its Adeno-associated virus (AAV) Test · Persbericht

18 maart 2021 · Sarepta Therapeutics’ Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Expression and Functional Improvements 2 Years After Administration · Persbericht

15 maart 2021 · Sarepta Therapeutics to Present Results from its Gene Therapy and RNA Platforms at the 2021 Annual MDA Clinical and Scientific Conference · Persbericht

25 februari 2021 · Sarepta Therapeutics Announces FDA Approval of AMONDYS 45™ (casimersen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 45 · Persbericht

24 februari 2021 · Sarepta Therapeutics to Present at Upcoming Investor Conferences · Persbericht

22 februari 2021 · Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2020 Financial Results and Recent Corporate Developments on March 1, 2021 · Persbericht

5 februari 2021 · SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT · Persbericht

4 februari 2021 · Sarepta Therapeutics Announces Winners of the “Rare Lessons” Lesson Planning Competition · Persbericht

1 februari 2021 · ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm · Persbericht

13 januari 2021 · Sarepta Therapeutics and Genevant Sciences Announce Research Collaboration for Lipid Nanoparticle-Based Gene Editing Therapeutics · Persbericht

9 januari 2021 · SRPT EQUITY ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Announces Investigation of Securities Claims Against Sarepta Therapeutics, Inc.; Encourages Investors with Losses Exceeding $1 Million to Contact Firm - SRPT · Persbericht

9 januari 2021 · SRPT INVESTIGATION ALERT: Bernstein Liebhard is Investigating Sarepta Therapeutics, Inc. For Violations of the Securities Laws · Persbericht

8 januari 2021 · Sarepta Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference · Persbericht

7 januari 2021 · Sarepta Therapeutics Announces Top-line Results for Part 1 of Study 102 Evaluating SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy · Persbericht

1 januari 2021 · Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

Mijn selecties